Celldex/CLDX

$39.25

-3.96%
-
1D1W1MYTD1YMAX

About Celldex

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Company’s bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Ticker

CLDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Anthony Marucci

Employees

160

Headquarters

Hampton, United States

Celldex Metrics

BasicAdvanced
$2.52B
Market cap
-
P/E ratio
-$2.91
EPS
1.58
Beta
-
Dividend rate
$2.52B
1.57975
$53.18
$22.11
962.18K
13.87
-34.56%
-37.45%
-36.8%
366.696
5.103
6.279
192.02%
-21.4%
-2.46%

What the Analysts think about Celldex

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
80.15% upside
High $90.00
Low $35.00
$39.25
Current price
$70.71
Average price target

Celldex Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,056.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$4.1M
173.33%
Net income
$-43.3M
13.35%
Profit margin
-1,056.09%
-58.53%

Celldex Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 11.6%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.62
-$0.65
-$0.81
-$0.83
-
Expected
-$0.63
-$0.67
-$0.68
-$0.74
-$0.69
Surprise
-1.9%
-2.5%
19.37%
11.6%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Celldex stock?

Celldex (CLDX) has a market cap of $2.52B as of April 13, 2024.

What is the P/E ratio for Celldex stock?

The price to earnings (P/E) ratio for Celldex (CLDX) stock is 0 as of April 13, 2024.

Does Celldex stock pay dividends?

No, Celldex (CLDX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Celldex dividend payment date?

Celldex (CLDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Celldex?

Celldex (CLDX) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Celldex stock price target?

The target price for Celldex (CLDX) stock is $70.71, which is 80.15% above the current price of $39.25. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Celldex stock

Buy or sell Celldex stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing